67,459 Shares in Valeant Pharmaceuticals Intl Inc (VRX) Acquired by Allianz Asset Management GmbH

Allianz Asset Management GmbH purchased a new position in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 67,459 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,411,000.

A number of other hedge funds also recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its stake in Valeant Pharmaceuticals Intl by 327.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,472,185 shares of the specialty pharmaceutical company’s stock worth $64,086,000 after purchasing an additional 3,426,410 shares in the last quarter. Legal & General Group Plc raised its position in shares of Valeant Pharmaceuticals Intl by 10.3% during the 3rd quarter. Legal & General Group Plc now owns 1,583,651 shares of the specialty pharmaceutical company’s stock valued at $22,638,000 after buying an additional 147,981 shares in the last quarter. Private Management Group Inc. raised its position in shares of Valeant Pharmaceuticals Intl by 21.6% during the 4th quarter. Private Management Group Inc. now owns 1,255,723 shares of the specialty pharmaceutical company’s stock valued at $26,094,000 after buying an additional 223,170 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Valeant Pharmaceuticals Intl by 21.9% during the 4th quarter. The Manufacturers Life Insurance Company now owns 1,226,232 shares of the specialty pharmaceutical company’s stock valued at $25,482,000 after buying an additional 220,299 shares in the last quarter. Finally, Schroder Investment Management Group raised its position in shares of Valeant Pharmaceuticals Intl by 2,951.5% during the 4th quarter. Schroder Investment Management Group now owns 1,113,800 shares of the specialty pharmaceutical company’s stock valued at $29,182,000 after buying an additional 1,077,300 shares in the last quarter. Institutional investors and hedge funds own 50.09% of the company’s stock.

How to Become a New Pot Stock Millionaire

Valeant Pharmaceuticals Intl stock opened at $15.37 on Friday. The company has a market cap of $5,567.50, a PE ratio of 2.25, a P/E/G ratio of 0.33 and a beta of -0.28. Valeant Pharmaceuticals Intl Inc has a fifty-two week low of $8.31 and a fifty-two week high of $24.43. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 4.25.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.96 by $0.02. The company had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.18 billion. Valeant Pharmaceuticals Intl had a net margin of 27.56% and a return on equity of 42.48%. The firm’s revenue was down 10.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.26 EPS. equities analysts predict that Valeant Pharmaceuticals Intl Inc will post 3.11 earnings per share for the current fiscal year.

Several brokerages have recently issued reports on VRX. HC Wainwright set a $24.00 target price on shares of Valeant Pharmaceuticals Intl and gave the company a “hold” rating in a research report on Tuesday, January 16th. Zacks Investment Research cut shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “strong sell” rating in a research report on Saturday, January 13th. TD Securities upped their target price on shares of Valeant Pharmaceuticals Intl from $20.00 to $27.00 and gave the company a “buy” rating in a research report on Friday, January 5th. Wells Fargo restated a “sell” rating on shares of Valeant Pharmaceuticals Intl in a research report on Thursday, January 4th. Finally, Goldman Sachs began coverage on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, January 24th. They set a “sell” rating and a $18.00 target price on the stock. Seven investment analysts have rated the stock with a sell rating, ten have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $18.30.

In related news, Director Schutter Richard U. De bought 10,000 shares of the company’s stock in a transaction on Thursday, March 8th. The shares were acquired at an average cost of $15.34 per share, for a total transaction of $153,400.00. Following the purchase, the director now directly owns 106,062 shares of the company’s stock, valued at $1,626,991.08. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Paul Herendeen bought 15,000 shares of the company’s stock in a transaction on Tuesday, March 13th. The stock was bought at an average price of $16.10 per share, for a total transaction of $241,500.00. The disclosure for this purchase can be found here. Insiders acquired a total of 7,121,629 shares of company stock worth $109,702,487 over the last 90 days. Insiders own 5.87% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “67,459 Shares in Valeant Pharmaceuticals Intl Inc (VRX) Acquired by Allianz Asset Management GmbH” was published by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3298183/67459-shares-in-valeant-pharmaceuticals-intl-inc-vrx-acquired-by-allianz-asset-management-gmbh.html.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Whiting Petroleum  Sets New 52-Week High and Low at $40.47
Whiting Petroleum Sets New 52-Week High and Low at $40.47
SilverBow Resources  Reaches New 52-Week High and Low at $34.76
SilverBow Resources Reaches New 52-Week High and Low at $34.76
Financial Comparison: Service Co. International  versus Yelp
Financial Comparison: Service Co. International versus Yelp
Critical Contrast: Morgan Stanley  and Its Competitors
Critical Contrast: Morgan Stanley and Its Competitors
Barfresh Food Group  vs. Lamb Weston  Head to Head Survey
Barfresh Food Group vs. Lamb Weston Head to Head Survey
Royal Bank of Canada Increases American Express  Price Target to $86.00
Royal Bank of Canada Increases American Express Price Target to $86.00


© 2006-2018 Ticker Report. Google+.